Venetoclax and ibrutinib and drug combinations for CLL
Present issues in treating patients with relapsed/refractory CLL
Advancements in APL treatment: oral ATO, MRD and treatment objectives
Graft versus host disease: how to treat it?
Inherited and acquired genetic factors involved in the development of CLL
John Gribben et al.